Comparing Benefit and Costs for Abira... - Fight Prostate Ca...

Fight Prostate Cancer

2,875 members1,109 posts

Comparing Benefit and Costs for Abiraterone and Enzalutamide in Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer

cujoe profile image
0 Replies

Summary article from MedPage Today's 'ASCO Reading Room'. Too bad our heath care comes down to cost-benefit analysis.

From the article:

"Ultimately, abiraterone and enzalutamide provide clinical benefit across all approved settings and have higher cost when used earlier in the course of metastatic prostate cancer. Value frameworks only contribute to, rather than completely define, the value of cancer therapies, and therefore additional measures will be needed to fully characterize value in cancer care."

Link to article:

Comparing Benefit and Costs for Abiraterone and Enzalutamide in Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer

medpagetoday.com/reading-ro...?

And here is a link to a MedPageToday interview with one of the research authors:

Srikala Sridhar, MD, on Abiraterone and Enzalutamide in Advanced Prostate Cancer

medpagetoday.com/asco/non-p...?

Stay Well - K9

Written by
cujoe profile image
cujoe
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

Arnab Basu, MD, on Breaking the Barriers to Genetic Counseling in Prostate Cancer - ASCO Reading Room - MedPage Today - 04.07.2021

Why are so few eligible patients currently being referred? Short interview on the...

Six big things in metastatic prostate cancer

Those members of the Fight Prostate Cancer hub of the HU site, who follow or intend to follow, the...

FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer

From several day ago. A new treatment tool for mCRPC patients with BRCA mutations. From the FDA:...

Consider Genetic Testing in All Metastatic Prostate Cancers— Expert panel recommendations from MedPage Today - June 10, 2020

At last some definitive support for genetic testing for PCa patients. From the MedPage Today...

Making a Case for Intermittent ADT in Metastatic Hormone Sensitive Prostate Cancer

FPC'ers, Many times, we hear people claim that you should only stop ADT if you can't tolerate it...